PAO Group（PAOG）株式概要PAO Group, Inc.は、代替医療に重点を置いている。 詳細PAOG ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析US市場と比較して、過去 3 か月間の株価の変動が非常に大きい財務データは報告されていない 意味のある時価総額がありません ( $573K )すべてのリスクチェックを見るPAOG Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0003該当なし内在価値ディスカウントEst. Revenue$PastFuture012016201920222025202620282031Revenue US$1.0Earnings US$0.1AdvancedSet Fair ValueView all narrativesPAO Group, Inc. 競合他社Altamira TherapeuticsSymbol: OTCPK:CYTO.FMarket cap: US$400.1kEcofibreSymbol: OTCPK:EOFB.FMarket cap: US$366.6kAspire Biopharma HoldingsSymbol: NasdaqCM:ASBPMarket cap: US$919.4kProPhase LabsSymbol: OTCPK:PRPHMarket cap: US$950.6k価格と性能株価の高値、安値、推移の概要PAO Group過去の株価現在の株価US$0.000352週高値US$0.000852週安値US$0.000001ベータ01ヶ月の変化50.00%3ヶ月変化-50.00%1年変化29,900.00%3年間の変化200.00%5年間の変化-93.66%IPOからの変化-99.90%最新ニュースお知らせ • Mar 20PAO Group, Inc. Announces Resignation of James Schramm as Chief Executive Officer, Effective March 18, 2026PAO Group, Inc. announced that James Schramm has resigned as Chief Executive Officer and that the Purchase and Sale Agreement dated July 21, 2025 has been formally rescinded, effective March 18, 2026, pursuant to a mutual agreement between Mr. Schramm and PAO Group, Inc. Under the terms of the rescission, Law90, LLC will be returned to James Schramm, and Mr. Schramm will return 3,510,000 Preferred C shares of PAO Group, Inc. to James C. DiPrima. Mr. Schramm intends to convey Law90, LLC to Green Stream Holdings, Inc. (“GSFI”). Law90, LLC is a Company which refers cases to attorneys which are members of Law90, LLC. The Company remains focused on advancing its strategic initiatives, strengthening operational continuity, and positioning PAOG for long-term growth. Additional updates regarding leadership and corporate developments will be provided as appropriate.お知らせ • Jun 22PAO Group, Inc. Confirms CBD Nutraceuticals Business Development Update to Include ALKM, USMJ and PURA Highlights Scheduled on June 23, 2021PAO Group, Inc. confirmed CBD Nutraceuticals Business Development Update on June 23, 2021. PAOG plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor. The update on Wednesday will include highlights on ALKM and USMJ roles in PAOG’s CBD Nutraceuticals Business Development. The update will also include an update on the intended distribution of PAOG stock to PURA (OTC Pink: PURA) shareholders in conjunction with PAOG’s acquisition of PURA’s cannabis cultivation operation.お知らせ • Jun 18PAOG Plans to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. confirmed the company’s plan to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. Next week, on June 23, management will release an update on the company’s CBD Nutraceuticals development initiative to include new developments expected to expand company’s overall market opportunity. The company is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.お知らせ • May 08Pao Group, Inc. Releases Preview of the Company's Plan to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. released preview of the company's plan to launch CBD Nutraceuticals line of products. PAOG's CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method. Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals. The first CBD Nutraceutical under development will sell under the name CBD RELAX-RX targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The second CBD Nutraceutical under development will be derived from PAOG's ongoing COPD research targeting the COPD treatment market separately from the pharmaceutical market also targeting COPD treatment. The third CBD Nutraceutical is being developed in partnership with the EVERx CBD Sports Water Brand owned by Puration, Inc. and will target the sports nutrition market. PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. as a copacker and North American Cannabis Holdings, Inc. as a distributor.お知らせ • Oct 16PAO Expects to Finalize Cro Engagement for Cannabis Drug Within Next Two WeeksPAO Group, Inc. published a progress update on the company's ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks. The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval. In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. In conjunction with PAOG's acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. to develop a proprietary cultivar to support PAOG's cannabis pharmaceutical treatment objectives. PAOG's Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments. PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.お知らせ • Jul 18PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY).PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY) on July 16, 2020. PAO Group agreed to acquire NCM Biotech in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in a dividend distribution. The NCM Biotech sale marks an exit from the cannabis industry for KALY. The transaction is expected to be complete by the end of July 2020.最新情報をもっと見るRecent updatesお知らせ • Mar 20PAO Group, Inc. Announces Resignation of James Schramm as Chief Executive Officer, Effective March 18, 2026PAO Group, Inc. announced that James Schramm has resigned as Chief Executive Officer and that the Purchase and Sale Agreement dated July 21, 2025 has been formally rescinded, effective March 18, 2026, pursuant to a mutual agreement between Mr. Schramm and PAO Group, Inc. Under the terms of the rescission, Law90, LLC will be returned to James Schramm, and Mr. Schramm will return 3,510,000 Preferred C shares of PAO Group, Inc. to James C. DiPrima. Mr. Schramm intends to convey Law90, LLC to Green Stream Holdings, Inc. (“GSFI”). Law90, LLC is a Company which refers cases to attorneys which are members of Law90, LLC. The Company remains focused on advancing its strategic initiatives, strengthening operational continuity, and positioning PAOG for long-term growth. Additional updates regarding leadership and corporate developments will be provided as appropriate.お知らせ • Jun 22PAO Group, Inc. Confirms CBD Nutraceuticals Business Development Update to Include ALKM, USMJ and PURA Highlights Scheduled on June 23, 2021PAO Group, Inc. confirmed CBD Nutraceuticals Business Development Update on June 23, 2021. PAOG plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor. The update on Wednesday will include highlights on ALKM and USMJ roles in PAOG’s CBD Nutraceuticals Business Development. The update will also include an update on the intended distribution of PAOG stock to PURA (OTC Pink: PURA) shareholders in conjunction with PAOG’s acquisition of PURA’s cannabis cultivation operation.お知らせ • Jun 18PAOG Plans to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. confirmed the company’s plan to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. Next week, on June 23, management will release an update on the company’s CBD Nutraceuticals development initiative to include new developments expected to expand company’s overall market opportunity. The company is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.お知らせ • May 08Pao Group, Inc. Releases Preview of the Company's Plan to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. released preview of the company's plan to launch CBD Nutraceuticals line of products. PAOG's CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method. Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals. The first CBD Nutraceutical under development will sell under the name CBD RELAX-RX targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The second CBD Nutraceutical under development will be derived from PAOG's ongoing COPD research targeting the COPD treatment market separately from the pharmaceutical market also targeting COPD treatment. The third CBD Nutraceutical is being developed in partnership with the EVERx CBD Sports Water Brand owned by Puration, Inc. and will target the sports nutrition market. PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. as a copacker and North American Cannabis Holdings, Inc. as a distributor.お知らせ • Oct 16PAO Expects to Finalize Cro Engagement for Cannabis Drug Within Next Two WeeksPAO Group, Inc. published a progress update on the company's ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks. The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval. In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. In conjunction with PAOG's acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. to develop a proprietary cultivar to support PAOG's cannabis pharmaceutical treatment objectives. PAOG's Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments. PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.お知らせ • Jul 18PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY).PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY) on July 16, 2020. PAO Group agreed to acquire NCM Biotech in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in a dividend distribution. The NCM Biotech sale marks an exit from the cannabis industry for KALY. The transaction is expected to be complete by the end of July 2020.株主還元PAOGUS PharmaceuticalsUS 市場7D0%0.1%1.6%1Y29,900.0%41.1%28.5%株主還元を見る業界別リターン: PAOG過去 1 年間で41.1 % の収益を上げたUS Pharmaceuticals業界を上回りました。リターン対市場: PAOG過去 1 年間で28.5 % の収益を上げたUS市場を上回りました。価格変動Is PAOG's price volatile compared to industry and market?PAOG volatilityPAOG Average Weekly Movement58.3%Pharmaceuticals Industry Average Movement9.8%Market Average Movement7.2%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.0%安定した株価: PAOGの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: PAOGの 週次ボラティリティ は過去 1 年間で3490%から58%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aJim DiPrimawww.pao.groupPAO Group, Inc.は代替患者ケア治療に注力している。同社は子会社を通じて、慢性・末期患者の治療のためのプレミアム医療用大麻製品の開発、販売、流通に従事している。本社はオハイオ州サンダスキー。もっと見るPAO Group, Inc. 基礎のまとめPAO Group の収益と売上を時価総額と比較するとどうか。PAOG 基礎統計学時価総額US$573.06k収益（TTM）US$0売上高(TTM)n/an/aPER（株価収益率n/aP/SレシオPAOG は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PAOG 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$0収益US$0直近の収益報告該当なし次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%PAOG の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/31 15:35終値2026/05/29 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PAO Group, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 20PAO Group, Inc. Announces Resignation of James Schramm as Chief Executive Officer, Effective March 18, 2026PAO Group, Inc. announced that James Schramm has resigned as Chief Executive Officer and that the Purchase and Sale Agreement dated July 21, 2025 has been formally rescinded, effective March 18, 2026, pursuant to a mutual agreement between Mr. Schramm and PAO Group, Inc. Under the terms of the rescission, Law90, LLC will be returned to James Schramm, and Mr. Schramm will return 3,510,000 Preferred C shares of PAO Group, Inc. to James C. DiPrima. Mr. Schramm intends to convey Law90, LLC to Green Stream Holdings, Inc. (“GSFI”). Law90, LLC is a Company which refers cases to attorneys which are members of Law90, LLC. The Company remains focused on advancing its strategic initiatives, strengthening operational continuity, and positioning PAOG for long-term growth. Additional updates regarding leadership and corporate developments will be provided as appropriate.
お知らせ • Jun 22PAO Group, Inc. Confirms CBD Nutraceuticals Business Development Update to Include ALKM, USMJ and PURA Highlights Scheduled on June 23, 2021PAO Group, Inc. confirmed CBD Nutraceuticals Business Development Update on June 23, 2021. PAOG plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor. The update on Wednesday will include highlights on ALKM and USMJ roles in PAOG’s CBD Nutraceuticals Business Development. The update will also include an update on the intended distribution of PAOG stock to PURA (OTC Pink: PURA) shareholders in conjunction with PAOG’s acquisition of PURA’s cannabis cultivation operation.
お知らせ • Jun 18PAOG Plans to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. confirmed the company’s plan to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. Next week, on June 23, management will release an update on the company’s CBD Nutraceuticals development initiative to include new developments expected to expand company’s overall market opportunity. The company is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
お知らせ • May 08Pao Group, Inc. Releases Preview of the Company's Plan to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. released preview of the company's plan to launch CBD Nutraceuticals line of products. PAOG's CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method. Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals. The first CBD Nutraceutical under development will sell under the name CBD RELAX-RX targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The second CBD Nutraceutical under development will be derived from PAOG's ongoing COPD research targeting the COPD treatment market separately from the pharmaceutical market also targeting COPD treatment. The third CBD Nutraceutical is being developed in partnership with the EVERx CBD Sports Water Brand owned by Puration, Inc. and will target the sports nutrition market. PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. as a copacker and North American Cannabis Holdings, Inc. as a distributor.
お知らせ • Oct 16PAO Expects to Finalize Cro Engagement for Cannabis Drug Within Next Two WeeksPAO Group, Inc. published a progress update on the company's ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks. The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval. In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. In conjunction with PAOG's acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. to develop a proprietary cultivar to support PAOG's cannabis pharmaceutical treatment objectives. PAOG's Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments. PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.
お知らせ • Jul 18PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY).PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY) on July 16, 2020. PAO Group agreed to acquire NCM Biotech in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in a dividend distribution. The NCM Biotech sale marks an exit from the cannabis industry for KALY. The transaction is expected to be complete by the end of July 2020.
お知らせ • Mar 20PAO Group, Inc. Announces Resignation of James Schramm as Chief Executive Officer, Effective March 18, 2026PAO Group, Inc. announced that James Schramm has resigned as Chief Executive Officer and that the Purchase and Sale Agreement dated July 21, 2025 has been formally rescinded, effective March 18, 2026, pursuant to a mutual agreement between Mr. Schramm and PAO Group, Inc. Under the terms of the rescission, Law90, LLC will be returned to James Schramm, and Mr. Schramm will return 3,510,000 Preferred C shares of PAO Group, Inc. to James C. DiPrima. Mr. Schramm intends to convey Law90, LLC to Green Stream Holdings, Inc. (“GSFI”). Law90, LLC is a Company which refers cases to attorneys which are members of Law90, LLC. The Company remains focused on advancing its strategic initiatives, strengthening operational continuity, and positioning PAOG for long-term growth. Additional updates regarding leadership and corporate developments will be provided as appropriate.
お知らせ • Jun 22PAO Group, Inc. Confirms CBD Nutraceuticals Business Development Update to Include ALKM, USMJ and PURA Highlights Scheduled on June 23, 2021PAO Group, Inc. confirmed CBD Nutraceuticals Business Development Update on June 23, 2021. PAOG plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion, and it is expected to reach $16.4 Billion by 2027. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor. The update on Wednesday will include highlights on ALKM and USMJ roles in PAOG’s CBD Nutraceuticals Business Development. The update will also include an update on the intended distribution of PAOG stock to PURA (OTC Pink: PURA) shareholders in conjunction with PAOG’s acquisition of PURA’s cannabis cultivation operation.
お知らせ • Jun 18PAOG Plans to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. confirmed the company’s plan to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021, is on track. The company also continues in the long-term CBD pharmaceutical. Next week, on June 23, management will release an update on the company’s CBD Nutraceuticals development initiative to include new developments expected to expand company’s overall market opportunity. The company is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
お知らせ • May 08Pao Group, Inc. Releases Preview of the Company's Plan to Launch CBD Nutraceuticals Line of ProductsPAO Group, Inc. released preview of the company's plan to launch CBD Nutraceuticals line of products. PAOG's CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments. PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder derived from a patented cannabis extraction method. Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals. The first CBD Nutraceutical under development will sell under the name CBD RELAX-RX targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The second CBD Nutraceutical under development will be derived from PAOG's ongoing COPD research targeting the COPD treatment market separately from the pharmaceutical market also targeting COPD treatment. The third CBD Nutraceutical is being developed in partnership with the EVERx CBD Sports Water Brand owned by Puration, Inc. and will target the sports nutrition market. PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. as a copacker and North American Cannabis Holdings, Inc. as a distributor.
お知らせ • Oct 16PAO Expects to Finalize Cro Engagement for Cannabis Drug Within Next Two WeeksPAO Group, Inc. published a progress update on the company's ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks. The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD) toward FDA approval. In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis. In conjunction with PAOG's acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. to develop a proprietary cultivar to support PAOG's cannabis pharmaceutical treatment objectives. PAOG's Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments. PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.
お知らせ • Jul 18PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY).PAO Group, Inc. (OTCPK:PAOG) agreed to acquire NCM Biotech from Kali, Inc. (OTCPK:KALY) on July 16, 2020. PAO Group agreed to acquire NCM Biotech in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in a dividend distribution. The NCM Biotech sale marks an exit from the cannabis industry for KALY. The transaction is expected to be complete by the end of July 2020.
